PARKINSON’S DISEASE

 

Tetrahydrocannabinol potentiates reserpine-induced hypokinesia.                   (abst – 1981)

http://www.ncbi.nlm.nih.gov/pubmed/6273940

 

Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia.                                                       (abst – 1985)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=142

 

Open label evaluation of cannabidiol in dystonic movement disorders.                   (full – 1986)

http://web.acsalaska.net/~warmgun/es017.html

 

The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease (PD).                                                                 (abst – 1998)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=153

 

Cannabinoids in parkinsonism                        (3 abstracts – 1999)

http://www.mdvu.org/emove/article.asp?ID=586

 

Cannabis in movement disorders.                 (abst – 1999)

http://www.ncbi.nlm.nih.gov/pubmed/10627163

 

Why your brain is primed for a high                (news – 1999)    (may need registration)

http://www.newscientist.com/article/mg16121792.000-why-your-brain-is-primed-for-a-high.html

 

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease                                                           (full – 2000)  http://www.fasebj.org/cgi/content/full/14/10/1432?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=  cannabis&andorexactfulltext=and&searchid=1&FIRSTINDEX=20&sortspec=relevance&resourcetype=H   WCIT

 

Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.                                                          (full – 2002)     http://www.jneurosci.org/content/22/16/6900.long

 

US Patent 6630507 – Cannabinoids as antioxidants and neuroprotectants             (full – 2003)

http://www.patentstorm.us/patents/6630507/fulltext.html

 

Therapeutic potential of cannabinoids in CNS disease.               (abst – 2003)

http://www.ncbi.nlm.nih.gov/pubmed/12617697

 

Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms.         (abst – 2004)

http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=33

 

Marijuana Compounds May Aid Parkinson’s Disease              (news – 2004)

http://cannabisnews.com/news/19/thread19725.shtml

 

Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)                                                                        (full – 2005)  http://www.nature.com/tpj/journal/v5/n2/full/6500301a.html

 

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.                                               (abst – 2005)  http://www.ncbi.nlm.nih.gov/pubmed/15837565?dopt=Abstract

 

Cannabinoid control of motor function at the basal ganglia.              (abst – 2005)

http://www.ncbi.nlm.nih.gov/pubmed/16596785

 

Cannabinoids In Medicine: A Review Of Their Therapeutic Potential                  (full – 2006)

http://www.doctordeluca.com/Library/WOD/WPS3-MedMj/CannabinoidsMedMetaAnalysis06.pdf

 

Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson’s disease: role of CB1 and TRPV1 receptors                                                   (full – 2007)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2128772/?tool=pmcentrez

 

The endocannabinoid system in targeting inflammatory neurodegenerative diseases (full – 2007)

 

http://medicalcannabis.com/images/pdf09/indications/neurodegenerative/centonze_et_al_2007_inflammato ry_neuro.pdf

 

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. (abst – 2007)                                     http://www.ncbi.nlm.nih.gov/pubmed/17196181

 

Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models.       (abst – 2007)                              http://www.ncbi.nlm.nih.gov/pubmed/17287809

 

Cannabinoids and neuroprotection in motor-related disorders.              (abst – 2007)

http://www.ncbi.nlm.nih.gov/pubmed/18220777

 

Marijuana Against Parkinson?               (news – 2007)

http://news.softpedia.com/news/Marijuana-Against-Parkinson-46701.shtml

 

Marijuana-Like Chemicals Helps Treat Parkinson’s                (news – 2007)

http://cannabisnews.com/news/22/thread22608.shtml

 

Parkinsons’ Helped By Marijuana-Like Chemicals In Brain               (news – 2007)

http://www.medicalnewstoday.com/releases/62616.php

 

Enhancing Activity Of Marijuana-Like Chemicals In Brain Helps Treat Parkinson’s Symptoms In Mice   (news – 2007)  http://www.sciencedaily.com/releases/2007/02/070207171915.htm

 

Paraquat induces apoptosis in human lymphocytes: protective and rescue effects of glucose, cannabinoids and insulin-like growth factor-1.                                                         (abst – 2008)  http://www.ncbi.nlm.nih.gov/pubmed/18365879

 

The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson’s disease. (abst – 2008)  http://www.ncbi.nlm.nih.gov/pubmed/18538428

 

LSUHSC research reports new method to protect brain cells from diseases like Alzheimer’s          (news – 2008)                                 http://www.eurekalert.org/pub_releases/2008-08/lsuh-lrr082008.php

 

WIN55,212-2, a Cannabinoid Receptor Agonist, Protects Against Nigrostriatal Cell Loss in the MPTP Mouse Model of Parkinson’s Disease                                                 (full – 2009)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755595/?tool=pubmed

 

Cannabidiol: a promising drug for neurodegenerative disorders?              (full – 2009)

http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00065.x/full

 

The endocannabinoid system as a target for the treatment of motor dysfunction. (abst – 2009)

http://www.ncbi.nlm.nih.gov/pubmed/19220290?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPa   nel.Pubmed_RVDocSum&ordinalpos=54

 

Cannabidiol for the treatment of psychosis in Parkinson’s disease               (abst – 2009)  http://jop.sagepub.com/cgi/content/abstract/23/8/979?maxtoshow=&hits=80&RESULTFORMAT=&fulltex  t=cannabinoid&searchid=1&FIRSTINDEX=1920&resourcetype=HWCIT

 

Medical Marijuana and Parkinson’s Disease                (news – 2009)

https://www.marijuanadoctors.com/content/ailments/view/158?ailment=parkinson-s-disease

 

Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders      (full – 2010)                           http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2010.00144.x/full

 

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.                                                            (full – 2010)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848893/?tool=pubmed

 

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (link to PDF – 2010)                                               http://www.mdpi.com/1424-8247/3/8/2689

 

Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson’s disease in the rat.                                                            (abst – 2010)  http://www.ncbi.nlm.nih.gov/pubmed/20097273

 

Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction.                                         (full – 2011)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145842/?tool=pubmed

 

Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011)                                  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/

 

Prospects for cannabinoid therapies in basal ganglia disorders.              (full – 2011)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165947/

 

Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinson’s Disease                                                                             (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21568925/abstract/Therapeutic_Potential_of_Cann  abinoids_in_the_Treatment_of_Neuroinflammation_Associated_with_Parkinson%27s_Disease_

 

Regional changes in type 1 cannabinoid receptor availability in Parkinson’s disease in vivo           (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21459482/abstract/Regional_changes_in_type_1_c  annabinoid_receptor_availability_in_Parkinson%27s_disease_in_vivo_

 

Homeostatic changes of the endocannabinoid system in Parkinson’s disease. (abst – 2011)

http://www.unboundmedicine.com/medline/ebm/record/21412829/abstract/Homeostatic_changes_of_the_e ndocannabinoid_system_in_Parkinson%27s_disease_

 

Symptom-relieving and neuroprotective effects of the phytocannabinoid D(9) -THCV in animal models of Parkinson’s disease                                            (abst – 2011)

 

 

 

 

Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation.                                                              (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/22079984

 

New metabolic pathway for controlling brain inflammation                        (news – 2011)  http://www.news-medical.net/news/20111021/New-metabolic-pathway-for-controlling-brain-  inflammation.aspx

 

The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription (full – 2012)                                            http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02175.x/full

 

Cannabinoid modulation of neuroinflammatory disorders.                    (full – 2012)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386505/

 

Review article: The endocannabinoid system in normal and pathological brain ageing (abst – 2012)                                            http://www.ncbi.nlm.nih.gov/pubmed/23108550

 

The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.                                                           (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22192465

 

Δ(9) -THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson’s disease.     (abst – 2012)                                           http://www.ncbi.nlm.nih.gov/pubmed/22236282

 

The decrease of dopamine D(2)/D(3) receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB(1) cannabinoid receptors in Parkinson’s disease: A preliminary autoradiographic study with the selective dopamine D(2)/D(3) antagonist [(3)H]raclopride and the novel CB(1) inverse agonist [(125)I]SD7015.                                                (abst – 2012)         http://www.ncbi.nlm.nih.gov/pubmed/22421165

 

Cannabinoids and value-based decision making: implications for neurodegenerative disorders.    (abst – 2012)                                   http://www.ncbi.nlm.nih.gov/pubmed/23162787

 

Contribution of genetic variants to pain susceptibility in Parkinson disease

(abst – 2012)                    http://onlinelibrary.wiley.com/doi/10.1002/j.1532-2149.2012.00134.x/abstract

Share a link for